Navigation Links
Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Date:8/27/2007

EDISON, N.J., Aug. 27 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") and Ipca Laboratories Ltd. ("Ipca") announced today that they have entered in to a strategic alliance for the development, supply and marketing of generic pharmaceutical products for the U.S. prescription drug market. Under the Agreement, Ipca shall develop and register selected products for U.S. ANDA submission and Heritage retains sales and marketing rights to such products. The parties shall share net profits from the sales proceeds post-launch.

Commenting on the Agreement, Heritage President & CEO, Jeffrey Glazer, stated, "Our agreement with Ipca represents yet another important strategic partnership with an emerging, low cost developer and supplier of active ingredients and finished goods. These types of agreements enable Heritage to leverage our business model of strategic outsourcing to obtain a "virtually vertical" supply chain of quality generic products as we continue to expand our product offerings."

Heritage Pharmaceuticals Inc. is an emerging generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Heritage launched its U.S. label in 2006 and currently markets 3 products over 10 SKU's. The Company will continue to introduce its acquired multi-source generic product line during 2007-08 following its tradition of premier quality, value and service in generics.

Ipca Laboratories Ltd. is a fast growing fully integrated pharmaceutical company based in Mumbai, India engaged in the manufacturing and marketing of a range of pharmaceuticals with a thrust on international business. Ipca exports its Active Pharmaceutical Ingredients and Finished Dosages to over 110 countries across the globe, which contributed about 53% of the Company's total global income of $227mm in the financial year 2006-07. It has a strong focus on international business in the developed markets like Europe and North America.


'/>"/>
SOURCE Heritage Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NanoRite Innovation Center opens with small science, big promise
2. UW-Madison to receive $125M for bioenergy research center
3. WARF enters licensing agreements for stem cell products
4. Internet-enabled niche markets take center stage
5. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
6. TomoTherapy opens technical training center
7. Stem cell and regenerative medicine center to aid education and commerce
8. Mega-Metro Center may go beyond Chicago and Wisconsin
9. Software company enters health space with RFID solutions on hold
10. Former Fiserv exec to enter Business Hall of Fame
11. Berbee to expand at New Venture Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... applications consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding ... offers a broad range of contract analysis services for advanced applications. Services ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):